argenx FIRST LOOK: Proof of concept in primary Sjogren's disease
argenx announced favourable Phase 2 data for its RHO study in primary Sjogren's disease (SjD), supporting further development into Phase 3. While no details on the results were given, the go decision was supported by the safety, efficacy and biomarker results from the study. argenx thus enters in close pursuit of J&J's nipocalimab, which also reported positive SjD Phase 2 data earlier this year with plans to pursue further. We look forward to additional study details to compare both assets in the race for Sjogren's disease. € 435 TP and Buy rating reiterated.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.